title: Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer.
abstract: Potential benefits of neoadjuvant therapy for locally advanced gastric cancer include tumor downstaging and an increased R0 resection rate. Potential disadvantages include increased surgical complications. This study assesses postoperative morbidity and mortality by comparing patients undergoing gastrectomy with and without neoadjuvant chemotherapy. From October 1998 to July 2002, a total of 34 patients with locally advanced gastric cancer were placed on a phase II neoadjuvant chemotherapy protocol consisting of two cycles of CPT-11 (75 mg/m(2)) with cisplatin (25 mg/m(2)). Demographic, clinical, morbidity, and mortality data were compared for these patients (CHEMO) versus 85 patients undergoing gastrectomy without neoadjuvant chemotherapy (SURG). The CHEMO patients were more likely to be less than 70 years of age (P< or =0.01), have proximal tumors (P< or =0.01), and undergo proximal gastrectomy (P< or =0.025). Fifty-two percent of SURG patients had T3/T4 tumors compared to 19% of CHEMO patients, consistent with tumor downstaging. The R0 resection rate was similar (80%). Morbidity was 41% in CHEMO patients and 39% in SURG patients. There were five postoperative deaths (4.4%), two in the CHEMO group and three in the SURG group (P=NS). It was concluded that neoadjuvant chemotherapy with CPT-11 and cisplatin is not associated with increased postoperative morbidity compared to surgery alone. CPT-11-based neoadjuvant chemotherapy should be tested further in combined-modality treatment of gastric cancer.
authors.affiliation: Department of Surgery, New York University School of Medicine, New York University Cancer Institute, Bellevue Hospital Center, New York, New York 10016, USA. stuart.marcus@med.nyu.edu
authors.forename: Stuart G
authors.initials: SG
authors.lastname: Marcus
authors.forename: Daniel
authors.initials: D
authors.lastname: Cohen
authors.forename: Ke
authors.initials: K
authors.lastname: Lin
authors.forename: Kwok
authors.initials: K
authors.lastname: Wong
authors.forename: Scott
authors.initials: S
authors.lastname: Thompson
authors.forename: Adina
authors.initials: A
authors.lastname: Rothberger
authors.forename: Milan
authors.initials: M
authors.lastname: Potmesil
authors.forename: Spiros
authors.initials: S
authors.lastname: Hiotis
authors.forename: Elliot
authors.initials: E
authors.lastname: Newman
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002166:Camptothecin / Q000009:adverse effects* / Q000031:analogs & derivatives*; D002945:Cisplatin / Q000009:adverse effects; D005260:Female; D005743:Gastrectomy / Q000401:mortality*; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011183:Postoperative Complications / Q000401:mortality*; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin